Hello, and welcome, everybody, to Recursion's Q2 2025 Earnings Call. My name is Chris Gibson, and I'm the Co-Founder and CEO of Recursion. And I'm excited to share with you today some of the latest ...
Bullish option flow detected in Recursion Pharmaceuticals (RXRX) with 26,086 calls trading, 1.1x expected, and implied vol increasing almost 32 points to 119.88%. 10/31 weekly 6 calls and Oct-25 5.5 ...
Hi, everybody. I’m Chris Gibson, Co-Founder and CEO of Recursion, and I'm so delighted you've joined us today for our Q1 2024 Earnings Call -- L(earnings) Call, as we call it. And I want to run ...
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback